Artemether, a potent artemisinin derivative, is a
cornerstone in the global fight against malaria, particularly for treating Plasmodium falciparum malaria, the most severe form of the disease. As a key component of Artemisinin-based Combination Therapies (ACTs), it offers rapid action and high efficacy, making it an indispensable medication in endemic regions. The market for Artemether and its combinations is witnessing steady growth, driven by the persistent global burden of malaria and concerted efforts towards its eradication.
The Artemether Market is expected to register a CAGR of 4.5% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031. This growth reflects the ongoing need for effective antimalarial treatments and the continuous initiatives by global health organizations.
A primary driver for this market is the high global incidence of malaria cases. The emergence of drug-resistant malaria strains further underscores the critical need for potent antimalarials like Artemether, often in combination with other drugs such as Lumefantrine, which dominates the market as part of ACTs.
Government initiatives and support from international health organizations play a crucial role in driving the market. Programs aimed at malaria control and eradication, including mass drug administration and improved access to antimalarial treatments in low-income areas, significantly boost demand. For instance, India, which accounted for 66% of malaria cases in the WHO South-East Asia region in 2022, has national strategic plans to eliminate malaria by providing low-cost treatment.
In terms of product forms, antimalarial tablets held the highest market share, accounting for 80.5% in 2023, highlighting their ease of administration and widespread use in treatment programs. Injectable forms are also crucial for severe cases. Efforts to improve healthcare infrastructure and access to treatment in these regions are expected to further propel growth.
Despite the positive outlook, challenges such as the emergence of drug resistance and the persistent issue of substandard or counterfeit antimalarial drugs, particularly in regions like Nigeria and Côte d'Ivoire, can hinder market growth. However, ongoing research and development into new formulations and delivery methods, coupled with strong public health initiatives, will ensure Artemether remains a vital weapon in the ongoing battle against malaria.
About Us:
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, Chemicals and Materials.
According to WHO, India made strong progress in the fight against malaria, recording the largest reduction in cases in South-East Asia from 20 million in 2000 to about 5.6 million last year.
